IMR Press / CEOG / Volume 36 / Issue 2 / pii/1630635622158-1762313554

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Editorial
A putative role of versican in uterine leiomyomas
Show Less
1 Department of Obstetrics and Gynecology, Kobe University Graduate School of Medicine (Japan)
Clin. Exp. Obstet. Gynecol. 2009, 36(2), 74–75;
Published: 10 June 2009
Abstract

The extracellular matrix (ECM) has been thought to contribute to the pathogenesis of uterine leiomyomas. Uterine leiomyomas have abundant ECM components, including collagen, fibronectin, and glycosaminoglycans. Recent studies have demonstrated the overexpression of versican in uterine leiomyomas. Versican is a chondroitin sulfate proteoglycan that constitutes the main component of the ECM. However, the role of versican in the growth of uterine leiomyomas remains unknown. In this article a putative role of versican in uterine leiomyomas is discussed in association with cell proliferation and apoptosis.
Keywords
Versican
Leiomyoma
Extracellular matrix
Share
Back to top